Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Hepatology. 2014 Feb 18;59(4):1435–1447. doi: 10.1002/hep.26790

Figure 5. Intratumoral infiltration of Gr1+ myeloid cells is increased after sorafenib (SOR) treatment, and is prevented by CXCR4 inhibition in HCC.

Figure 5

A–B, After SOR treatment, the number of 7AAD–CD11b+Gr1+ monocytes (measured by flow cytometry) significantly increased in HCA-1 tumors growing C3H mice with liver fibrosis (A) of as well as in spontaneous HCCs in Mst1−/− Mst2F/− transgenic mice (B). Treatment with the CXCR4 inhibitor AMD3100 prevented this effect (A–B). C, The number of 7AAD–CD11b+Gr1+ myeloid cells was significantly reduced in the fibrotic liver tissues from sorafenib-treated mice. Data are shown as percentages of the total number of cells evaluated in enzymatically digested tissue. Data are presented as mean ± SEM (N=5–14 mice per group). **P<0.01.